Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 9Recruiting 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 12Gastrointestinal 7Tumor-Agnostic 4Genitourinary 3Thoracic 2Dermatologic 2CNS 2Plasma cell 1Other solid neoplasm 1Other 1Lymphoid 1Head & Neck 1Endocrine 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 20daratumumab 17Bortezomib 12Lenalidomide 11pomalidomide 8Cyclophosphamide 8Calcium Dobesilate 7belantamab mafodotin 5isatuximab 4fludarabine 4carfilzomib 4Melphalan 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Specimen Handling 3Biopsy 3tocilizumab 2iberdomide 2Stem Cell Transplantation 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Hyaluronoglucosaminidase 2Fluorodeoxyglucose F18 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2zanubrutinib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Standard of Care × Plasma cell × Clear all
NCT07181239 2025-09-18

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

Keymed Biosciences Co.Ltd

Phase 3 Not yet recruiting
280 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡